Parkwalk Advisors
Parkwalk Advisors Ltd is a London-based venture capital firm established in 2009, specializing in investments in early and growth-stage technology companies, particularly those spun out from UK universities and research institutions. The firm focuses on sectors such as healthcare, energy, materials, artificial intelligence, big data, cleantech, medtech, and quantum computing. Parkwalk seeks to invest in companies with strong intellectual property and a clear path to market, typically committing between £250,000 and £10 million per investment. The firm is stage agnostic, engaging in various rounds of funding, including seed and Series C and beyond. It emphasizes investments in unquoted companies and aims to generate capital gains for its investors, benefiting from favorable tax relief programs in the UK. Parkwalk leverages extensive networks in academia and venture capital to access high-quality deal flow. In 2017, Parkwalk became a subsidiary of IP Group Plc, enhancing its capabilities in intellectual property commercialization.
Oxford Endovascular
Series A in 2024
Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.
Opsydia
Venture Round in 2022
Opsydia is set to disrupt a number of industries by its ability to create practically invisible structures inside transparent materials. Permanent and inimitable serial numbers, images or cryptographic data can be laser-written without compromising the integrity of the material or modifying its surface. Material applications include diamond, glass and polymers
Oxford Endovascular
Series B in 2021
Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.
Oxford Endovascular
Series A in 2021
Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.
Oxa specializes in developing autonomous vehicle software that enhances the operational capabilities of fleets. The company offers an AI-based platform designed to facilitate the deployment and scaling of autonomous vehicles. Its software utilizes laser vision and radar technology to improve localization and redundancy, ensuring safe navigation in various environments, including pedestrian areas. By enabling autonomous systems to better understand their surroundings and predict the movements of other vehicles, Oxa supports businesses in integrating autonomy into their transportation solutions while maintaining low compute power requirements.
Oxa specializes in developing autonomous vehicle software that enhances the operational capabilities of fleets. The company offers an AI-based platform designed to facilitate the deployment and scaling of autonomous vehicles. Its software utilizes laser vision and radar technology to improve localization and redundancy, ensuring safe navigation in various environments, including pedestrian areas. By enabling autonomous systems to better understand their surroundings and predict the movements of other vehicles, Oxa supports businesses in integrating autonomy into their transportation solutions while maintaining low compute power requirements.
Opsydia
Seed Round in 2018
Opsydia is set to disrupt a number of industries by its ability to create practically invisible structures inside transparent materials. Permanent and inimitable serial numbers, images or cryptographic data can be laser-written without compromising the integrity of the material or modifying its surface. Material applications include diamond, glass and polymers
Oxford Endovascular
Venture Round in 2018
Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.
Oxford Endovascular
Series A in 2015
Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.
Reduse Limited provides print removal services from paper using laser technology. Founded in 2015 by David Leal-Ayala, Hidde-Jan Lemstra, and Stuart Evans, the company is headquartered in Cambridge, United Kingdom. Reduse focuses on innovative solutions for recycling and reusing paper materials, offering a sustainable alternative to traditional methods of handling printed paper waste.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.